E-cigarette and vape uses more prone to infection

Industry InsightInnovation
Jul.22.2022
E-cigarette and vape uses more prone to infection

Rima, a 27-year-old Saudi woman, holds her electronic cigarette as she vapes at a coffee shop in downtown Riyadh, a sign of the changing times in Saudi Arabia - Copyright AFP/File JOHN THYS

Read more: https://www.digitaljournal.com/tech-science/e-cigarette-and-vape-uses-more-prone-to-infection/article#ixzz7ZkXgRHcoUsers of nicotine products are more susceptible to contracting an infection. One research study identified an abundance of Porphyromonas (a genus of Gram-negative bacteria implicated in periodontal disease) and Veillonella (a different group of Gram-negatives associated with cases of osteomyelitis and endocarditis) in higher levels among vapers, suggesting that vaping alters the oral microbiome. The oral microbiome has an established relationship to overall health and it is the second and most diverse microbiota next to the gut, home to over 1,000 species of microbes.

 

Disruptions to this community can lead to health implications. Of particular concern is the bacterium Porphyromonas gingivalis. Enzymes produced by the bacterium can attack collagen.
 

Periodontal, or gum, disease is one of the most common infectious diseases worldwide. In its more severe forms, such as periodontitis, the condition causes loss of the bone that supports the teeth. In addition to gum disease, the bacterium has been linked to rheumatoid arthritis.

 

Ecosystem stability can be affected by two types of disturbances: long-term influences or “presses” and short-term effects or “pulses”. Furthermore, the researchers discovered that interleukin (IL)-6 and IL-1?, a pro-inflammatory cytokines which indicate inflammatory responses, were highly elevated in e-cigarette users when compared with non-users. In particular, epithelial cell-exposed e-cigarette aerosols were more susceptible for infection. This led to the assessment that e-cigarette users are more prone to infection. This occurs because alterations to the microbial landscape, which accompanies higher levels of proteins in vapers’ mouths, signals that the immune system is more likely to activate and produce inflammation. In turn this exponentially increases the likelihood for disease.

 

Additionally, sequencing based studies have shown that certain species of bacteria (Haemophilus influenzae, Streptococcus pneumoniae, Staphylococcus aureus and Pseudomonas aeruginosa) are more strongly associated with the development of a
lung community skewed towards loss of diversity. Concerningly, these organisms are associated with declining lung function. It appears that e-cigarette vapor can change the way the bacteria grow, by increasing volume and the area covered by the bacteria, which can lead to infections if untreated.
 

The association between the oral cavity and disease is complex, with the pathogenicity of chronic periodontal disease a factor of the complex interaction of microbial pathogens, host immune response, and genetic and environmental factors. The drawing in of chemical vapor adds to the environmental complexity and appears to be a microbiome altering factor. However, what stands out from research is the general trend that the majority of the metagenome in e-cigarette users was shared by more than the majority of users, which contrasts with smokers and non-smokers, who do not tend to share their bacterial and fungal composition.

 

The content excerpted or reproduced in this article comes from a third-party, and the copyright belongs to the original media and author. If any infringement is found, please contact us to delete it. Any entity or individual wishing to forward the information, please contact the author and refrain from forwarding directly from here.

FDA Says Flavored ENDS Must Show “Added Benefit” as Small Manufacturers Seek Clearer Switching Benchmarks
FDA Says Flavored ENDS Must Show “Added Benefit” as Small Manufacturers Seek Clearer Switching Benchmarks
During the FDA PMTA roundtable session on “Studies of Adult Benefit,” officials said flavored ENDS must demonstrate “added benefit” over tobacco-flavored products under the APPH standard, including sustained complete switching evidence. Small manufacturers questioned switching benchmarks, study duration, and bridging expectations.
Feb.11
China Tobacco Hubei Industrial Co., Ltd Tests New Gas Release Nicotine Pouch Technology, According to Patent Documents
China Tobacco Hubei Industrial Co., Ltd Tests New Gas Release Nicotine Pouch Technology, According to Patent Documents
China Tobacco Hubei Industrial Co., Ltd applies for patents on new nicotine pouch technology with gas release feature.
Mar.04 by 2FIRSTS.ai
UK South East Seized 3.1M Illegal Vapes Since 2021 as Crackdown Intensifies
UK South East Seized 3.1M Illegal Vapes Since 2021 as Crackdown Intensifies
Illegal vape seizures in the UK South East have risen sharply over the past five years, with 2023 marking the high point. While single-use vapes were banned from sale in June 2025, enforcement teams say disposable products remain in circulation, fueling renewed calls for licensing and stronger enforcement funding.
Jan.23 by 2FIRSTS.ai
Ireland’s Tobacco and Vape Retail Licensing Regime Takes Effect; BAT Says It Should Cover Nicotine Pouches
Ireland’s Tobacco and Vape Retail Licensing Regime Takes Effect; BAT Says It Should Cover Nicotine Pouches
Ireland’s retail licensing system took effect on Feb. 2, 2026, charging annual fees per point of sale and enforced by the Health Service Executive (HSE). British American Tobacco’s local unit, BAT Ireland, said excluding nicotine pouches could leave a regulatory gap.
Feb.04 by 2FIRSTS.ai
West Virginia Bill Would Direct USD 2.9 Million of Juul Settlement to Youth Tobacco and Vaping Prevention
West Virginia Bill Would Direct USD 2.9 Million of Juul Settlement to Youth Tobacco and Vaping Prevention
A bill completed during West Virginia’s 2026 regular legislative session would make a one-time allocation of USD 2.9 million from the state’s USD 7.9 million settlement with Juul to youth tobacco prevention and cessation programs.
Mar.19 by 2FIRSTS.ai
FDA Outlines Manufacturing Requirements as Critical to ENDS PMTA Success
FDA Outlines Manufacturing Requirements as Critical to ENDS PMTA Success
FDA officials said manufacturing consistency is a core prerequisite for ENDS PMTA reviews, not a procedural formality. During its February 10, 2026 roundtable, the agency outlined expectations for quality management systems, manufacturing documentation, nicotine control, stability studies, and risk mitigation, emphasizing that robust manufacturing evidence underpins determinations of whether products are appropriate for the protection of public health.
Feb.11